These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36089982)

  • 1. Outcomes of Pediatric Patients with Crohn's Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission.
    Lv Y; Lou Y; Yang G; Luo Y; Lou J; Cheng Q; Yu J; Fang Y; Zhao H; Peng K; Chen J
    Gastroenterol Res Pract; 2022; 2022():3813915. PubMed ID: 36089982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease.
    Luo Y; Yu J; Lou J; Fang Y; Chen J
    Gastroenterol Res Pract; 2017; 2017():6595048. PubMed ID: 28928769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
    Jongsma MME; Vuijk SA; Cozijnsen MA; van Pieterson M; Norbruis OF; Groeneweg M; Wolters VM; van Wering HM; Hojsak I; Kolho KL; van Wijk MP; Teklenburg-Roord STA; de Meij TGJ; Escher JC; de Ridder L
    Eur J Pediatr; 2022 Aug; 181(8):3055-3065. PubMed ID: 35672586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of induction therapy with exclusive enteral nutrition in pediatric Crohn's disease].
    Luo YY; Fang YH; Yu JD; Xu LJ; Sun MF; Cheng Q; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun; 24(6):626-630. PubMed ID: 35762427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusive enteral nutrition effect on the clinical course of pediatric Crohn's disease: a single center experience.
    Scarpato E; Strisciuglio C; Martinelli M; Russo M; Cenni S; Casertano M; Serra MR; Staiano A; Miele E
    Eur J Pediatr; 2020 Dec; 179(12):1925-1934. PubMed ID: 32734315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis.
    Yu Y; Chen KC; Chen J
    World J Pediatr; 2019 Feb; 15(1):26-36. PubMed ID: 30666565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
    Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A
    BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients.
    Tang W; Hu W; Shi P; Ye Z; Wu J; Zhang Y; Wang Y; Huang Y
    Front Pediatr; 2022; 10():874425. PubMed ID: 35664880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study.
    Urlep D; Benedik E; Brecelj J; Orel R
    Eur J Pediatr; 2020 Mar; 179(3):431-438. PubMed ID: 31781933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines.
    Grover Z; Lewindon P
    Dig Dis Sci; 2015 Oct; 60(10):3069-74. PubMed ID: 26038093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Active Crohn's Disease in Children Using Partial Enteral Nutrition Combined with a Modified Crohn's Disease Exclusion Diet: A Pilot Prospective Cohort Trial on Clinical and Endoscopic Outcomes.
    Urlep D; Orel R; Kunstek P; Benedik E
    Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
    Day AS; Whitten KE; Lemberg DA; Clarkson C; Vitug-Sales M; Jackson R; Bohane TD
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1609-14. PubMed ID: 16928225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn's Disease and Emerging Combination Strategy With Biologics.
    Wands DIF; Gianolio L; Wilson DC; Hansen R; Chalmers I; Henderson P; Gerasimidis K; Russell RK
    Inflamm Bowel Dis; 2024 Aug; 30(8):1258-1263. PubMed ID: 37619221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Term Efficacy of Exclusive Enteral Nutrition in Pediatric Crohn's Disease: Practice in China.
    Luo Y; Yu J; Zhao H; Lou J; Chen F; Peng K; Chen J
    Gastroenterol Res Pract; 2015; 2015():428354. PubMed ID: 26106412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis.
    Connors J; Basseri S; Grant A; Giffin N; Mahdi G; Noble A; Rashid M; Otley A; Van Limbergen J
    J Crohns Colitis; 2017 Sep; 11(9):1063-1070. PubMed ID: 28575325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn's disease - a prospective multicentre trial.
    Matuszczyk M; Meglicka M; Landowski P; Czkwianianc E; Sordyl B; Szymańska E; Kierkuś J
    Prz Gastroenterol; 2021; 16(4):346-351. PubMed ID: 34976243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease.
    Soo J; Malik BA; Turner JM; Persad R; Wine E; Siminoski K; Huynh HQ
    Dig Dis Sci; 2013 Dec; 58(12):3584-91. PubMed ID: 24026403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.